AllSci News
GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate
GSK has agreed to pay USD 110 million upfront for exclusive rights to develop and commercialize HMPL-A830, a pre-clinical antibody-targeted therapy...
Ultragenyx’s Angelman setback puts UBE3A strategy under scrutiny
The Phase III Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary endpoint, leaving the condition without an approved...
TScan restructures around in vivo TCR-T, pauses Phase III hematology program
Waltham, Massachusetts-based TScan Therapeutics (Nasdaq: TCRX) announced a major restructuring that will shift the company away from near-term development...
Vincere Bio wins grant for USP30 inhibitor IND-enabling studies in acute kidney injury
Vincere Biosciences, a small molecule drug developer, has received a USD 1.3 million SBIR Phase II grant from the National Institute of Diabetes and...
Boston Children's Hospital picks up USD 3.9m NIH grant to target endometriosis pain via lipid receptors
Boston Children's Hospital has received a USD 3.9 million NIH R01 grant to identify specialized pro-resolving lipid mediator (SPM) receptors as druggable...
GentiBio secures NIH backing for allogeneic engineered Treg therapy in type 1 diabetes
Cambridge, Massachusetts-based GentiBio, Inc. has received a USD 1.07 million NIH R44 SBIR Phase II grant from the National Institute of Diabetes and...
Taveos' unraveling accelerates as UK joins global regulatory retreat
A rare autoimmune vasculitis treatment has lost its UK authorization after regulators concluded that data underpinning its approval can no longer be...
Boehringer Ingelheim licenses Owkin's K Pro AI platform and immunology data
Boehringer Ingelheim has licensed K Pro, the agentic AI Scientist platform developed by New York and Paris-based Owkin, along with multimodal patient data...
CytoDyn bags another USD 16.5m in PIPE deal to support CCR5-targeted leronlimab
Vancouver, Washington-based CytoDyn Inc. (OTCQB: CYDY) closed a USD 16.5 million private placement to sustain clinical operations and advance its...
Biocytogen grants Qilu non-exclusive license to preclinical VHH antibody for neuroscience
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SSE: 688796; HKEX: 02315) has granted Qilu Pharmaceutical Co., Ltd. a non-exclusive license to a...
Typewriter emerges with USD 56m to build non-viral in vivo CAR-T platform
Cambridge, Massachusetts-based Typewriter Therapeutics, Inc. has emerged from stealth with a USD 56 million Series A financing round to advance a non-viral,...
Novartis taps Alteogen in USD 3.2b subcutaneous biologics pact
Novartis has entered an option and license agreement with South Korea-based Alteogen Inc. (KOSDAQ: 196170) to develop and commercialize subcutaneous...
Keymed licenses approved IL-4Ralpha mAb stapokibart to Singapore firm Aeira for 18 Asian markets
Keymed Biosciences Inc. (HKEX: 02162) has licensed its approved IL-4Rα monoclonal antibody stapokibart (Kangyueda) to Singapore-based Aeira Pte. Ltd. for...
Adicet preps off-the-shelf gamma delta CAR-T for first-in-human prostate cancer study
Redwood City-based Adicet Bio (Nasdaq: ACET) has registered a Phase I/II trial of ADI-212, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell...
Korea's Pharos iBio, Kolon Pharma advance fourth-generation EGFR inhibitor into preclinical
South Korea-based Pharos iBio and Kolon Pharma have signed a joint research and development agreement to co-develop PHI-701, a preclinical EGFR-targeting...
The AllSci Brief
Free, systematic R&D and deal news. Daily.